PERSPECTIVES
The mammalian cerebral cortex is a complex network of highly interconnected areas which are each unique in their architecture, connections and function. Even though there is considerable information on the patterns of linkages between areas, there is surprisingly little information on the functional impact one region exerts over other regions. The information that is available is limited to electrophysiological studies on single neurons. In this analysis the authors combined cooling deactivation of a limited region of the cortex, with modified uptake of deoxyglucose as a marker of modified metabolism, and hence neural activity at the cooled and remote sites. Comparisons with anatomical measures show that for many laterally connected regions the functional impact can be predicted from the strength of the anatomical connections. In contrast, for many feedforward projections the anatomical strength provides an underestimate of functional strength. Yet for many feedback projections, the anatomy provides an overestimate, at least in the passive viewing condition tested. These conclusions suggest that the combination of cooling and deoxyglucose techniques may be extremely useful in providing measures of functional impact that go well beyond the inferences based purely on connectional data.
Neuroimaging abnormalities in the subgenual prefrontal cortex: implications for the pathophysiology of familial mood disorders WC Drevets, D Ö ngü r, JL Price
In a previous neuroimaging study, the authors demonstrated an abnormal reduction in grey matter volume in the prefrontal cortex (PFC) situated beneath the genu of the corpus callosum in familial major depressive disorder (MDD) and bipolar disorder (BD). To elucidate the nature of this subgenual PFC abnormality, a histopathological study of tissue acquired post mortem from subjects with MDD and BD was conducted and the preliminary results are described in this article. The reduction of cortical volume in this region was evident by microscopic analysis, and this abnormality was associated with a reduction of glial cells without an equivalent loss of neurons. Because the cortical glia play critical roles in providing energy substrates to neurons, maintaining potassium homeostasis in extracellular fluid, and taking up neurotransmitters, this abnormality may disturb subgenual PFC function. The implications of this finding for the pathogenesis of depressive symptoms are discussed in light of evidence that this region contributes to mediate the endocrine and autonomic responses to stress and in modulating reward-related mesolimbic dopamine transmission.
ORIGINAL RESEARCH ARTICLES
Superoxide, neuroleptics and the ubiquinone and cytochrome b 5 reductases in brain and lymphocytes from normals and schizophrenic patients SA Whatley, D Curti, F Das Gupta, IN Ferrier, S Jones, C Taylor, RM Marchbanks Neuroleptic medication for schizophrenia has been found to decrease oxidative stress. In experimental animals the neuroleptic flupenthixol reduces the expression of the gene coding for the enzyme NADHcytochrome b 5 reductase. Flupenthixol also reduces the enzymic activity of the mitochrondrial NADHubiquinone reductase. Both the cis-and therapeutically less active trans-stereo-isomers of flupenthixol were found to produce these changes in experimental animals. Post-mortem brain tissue from schizophrenics who had received neuroleptic medication have reduced levels of both reductases. Lymphocyte samples from schizophrenics also have reduced levels of both reductases as compared with normals. Together these enzymes play an important role in the energy metabolism of the brain, but it was shown with purified enzymes that they also produce the superoxide anion O − 2 as a neurotoxic by-product. Superoxide production is reduced in brain tissue and lymphocytes from schizophrenics receiving neuroleptic medication. The authors conclude that the neuroleptic flupenthixol causes a downregulation of the NADH-cytochrome b 5 reductase as well as the mitochondrial ubiquinone reductase, and, as a consequence a reduction in the brain production of neurotoxic superoxide. In their earlier studies they found that the changes in gene expression caused by flupenthixol are in the opposite direction to those found in schizophrenia. This suggests that the action of neuroleptics in reversing oxidative stress might also play a part in reversing the pathophysiological alterations found in schizophrenia.
Dopamine D4 receptor and serotonin transporter promoter in the determination of neonatal temperament RP Ebstein, J Levine, V Geller, J Auerbach, I Gritsenko, RH Belmaker
The role of two common genetic polymorphisms on the behavior of 2-week-old human infants was examined using the well-known Neonatal Behavioral Assessment Scale which was designed to evaluate the temperament of the newborn baby by assessing the baby's behavioral repertoire as he/she responds to human and nonhuman stimuli. The ways he/she uses states of consciousness to control responses reveals the capacity to respond to a new environment. The behavioral effects of two common polymorphisms, linked respectively in some studies to novelty seeking (dopamine D4 receptor) and neuroticism or harm avoidance (serotonin transporter promoter region) were examined in a group of 81 2-week-old neonates. Multivariate statistical tests of significance showed a significant association of the so-called 'novelty seeking' gene across four behavioral clusters pertinent to newborn temperament. The effect of the short variant of the so-called 'neuroticism gene' in those infants was to lower their NBAS orientation scores. Orientation may be understood as an active, attentive and searching process for infants, perhaps a neonatal precursor to adult novelty-seeking behavior. Thus, in infants as in adults, personality appears to be partially determined by the developmental interaction between underlying genetic mechanisms contributing respectively to behavioral activation and inhibition.
Toxic effects of acetylcholinesterase on neuronal and glial-like cells in vitro FH Calderó n, R von Bernhardi, G De Ferrari, S Luza, R Aldunate, NC Inestrosa
Alzheimer's disease (AD) is characterized by loss of memory and higher cognitive functions caused by neurodegeneration in specific brain regions. The mechanisms by which neuronal cell death arises in AD are still unclear, but it has been proposed that the amyloid-␤-peptide may be the primary cause of it. The selective nature of the neuronal populations damaged in AD suggests that other factors present in the senile plaques may also be involved. Acetylcholinesterase (AChE), the enzyme responsible for finishing the cholinergic transmission, has been shown to accelerate amyloid formation. The authors report here that AChE is toxic to neuronal and glial-like cells in vitro and this effect is not related to its catalytic activity. Nuclear DNA fragmentation analyses (TUNEL technique) indicated that apoptotic cell death can be induced by AChE. Those results suggest that AChE may play a role in the neuronal degeneration observed in AD. Previous studies have suggested a relationship between a polymorphism of the D 2 receptor gene and 'addictive' behaviors, such as alcoholism, nicotine smoking, or even gambling. One study in postmortem brain tissue suggested that this polymorphism might be associated with a lower number of D 2 receptors. These observations led to the hypothesis that subjects with this genetic trait would have fewer D 2 receptors, and a relative deficiency in dopamine function. This deficiency would make them more vulnerable to behaviors that increase dopamine function, such as alcoholism. In this study, the authors used a noninvasive brain imaging method to measure D 2 receptor density in a large cohort of subjects, and tried to replicate the association between this polymorphism and receptor density. In contrast to the postmortem study, they observed no relationship between this genetic marker and receptor expression. They conclude that this polymorphism plays only a minor role, if any, in the expression of D 2 receptors in humans.
Further support for an association between a polymorphic CAG repeat in the hKCa3 gene and schizophrenia T Bowen, CA Guy, N Craddock, AG Cardno, NM Williams, G Spurlock, KC Murphy, LA Jones, M Gray, RD Sanders, G McCarthy, KG Chandy, E Fantino, K Kalman, GA Gutman, JJ Gargus, J Williams, P McGuffin, MJ Owen, MC O'Donovan Recently, a novel calcium-activated potassium channel gene has been isolated which contains a CAG trinucleotide repeat in its DNA sequence that is variable in size in the general population. Previous studies have suggested that unknown large repeats of this type may be involved in the aetiology of schizophrenia. Therefore, it is of particular interest that the group that identified this gene has provided modest evidence that the larger sizes of this repeat are more common in people with schizophrenia than in unaffected individuals. The authors have investigated this in a UK/Eire sample of 194 schizophrenics and 183 group-matched controls. Using the same classification system of repeat size as the earlier study, they found that schizophrenics had a higher frequency of 'large' repeats than controls. These data therefore lend support to the hypothesis that polymorphism in the hKCa3 gene may contribute to susceptibility to schizophrenia, although the overall balance of evidence remains far from conclusive.
Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder CJ McDougle, CN Epperson, LH Price, J Gelernter
Genetic factors are known to influence risk for obsessive-compulsive disorder (OCD). OCD is treatable with medications that interact with the serotonin transporter protein, especially the selective serotonin reuptake inhibitors such as Prozac. In the present study, investigators used a family controlled association approach (the transmission disequilibrium test method) to identify linkage disequilibrium and association between the gene coding for the serotonin transporter protein and OCD. Due to the small sample size, the investigators stressed the preliminary nature of the results and the necessity for replication. If the results are confirmed in another sample, this would mean that the serotonin transporter protein gene is one of many influencing risk for OCD. It has been known for some time that a genetic polymorphism in the promoter region of this gene influences its function at least in vitro; this same polymorphism has previously been determined to be linked and associated with autism, and associated with neuroticism, anxiety, and depression.
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